NUDT15 and inflammatory bowel disease: For IBD, to date, pharmacogenetic research has also produced the most success in the context of molecular patient profiling (e.g., TPMT and NUDT15 genetic testing in the context of thiopurine-induced myelotoxicity, Table 2).